On Thursday, Wolfe Research raised its rating on iRhythm Technologies (NASDAQ:IRTC) stock, shifting from Peerperform to Outperform. The firm has set a price target for the stock at $115.00, indicating a positive outlook for the company's performance.
The upgraded status is influenced by what Wolfe Research considers a "sensible entry valuation." The previous fair value range for iRhythm Technologies was between $95 and $115. With the stock currently at $98, Wolfe Research expresses increased confidence, especially with the anticipation of a key overhang expected to be resolved within the next 12 months. This resolution is projected to elevate the stock to the higher end of the prior range, justifying the $115 price target.
Wolfe Research's valuation is supported by a discounted cash flow (DCF) analysis and a straightforward enterprise value (EV) to revenue comparison. The $115 price target is approximately 5 times iRhythm's projected 2025 revenue.
Historically, over the past year, the company's EV/revenue multiple has averaged 5.5 times, and since its initial public offering (IPO), it has been nearly 9 times. When compared to 30 small to mid-sized (SMID) medical technology companies that currently average nearly 3.5 times, Wolfe Research believes that a premium of 5 times is warranted for iRhythm.
The rationale behind the premium is based on iRhythm's revenue growth prospects. The group of 30 medical technology comparables is expected to see revenue growth in the low teens percentage range next year.
In contrast, Wolfe Research projects that iRhythm will experience high teens percentage revenue growth. It is this anticipated premium growth that supports the premium multiple assigned to iRhythm Technologies.
In other recent news, iRhythm Technologies reported a significant 18.4% year-over-year increase in revenue for the first quarter of 2024, reaching $131.9 million. This growth was attributed to strategic initiatives, new account openings, and partnerships with primary care networks. The company also announced plans for international expansion into European and Japanese markets.
iRhythm has also advanced the automation of its Zio monitor manufacturing. This development is expected to enhance operational efficiency and production capacity, potentially allowing the company to produce up to 10 million units annually. The company's CEO, Quentin Blackford, anticipates this will lead to increased global accessibility of iRhythm's products.
Despite concerns raised by The Capitol Forum regarding the Zio AT device, Wells Fargo maintained its Overweight rating on iRhythm's stock with a price target of $135.00. The company has consistently filed with the FDA's MAUDE database, reflecting its commitment to transparency and adherence to FDA guidelines.
iRhythm is also exploring the sleep apnea diagnostics market, with BTIG maintaining a Buy rating and a $132.00 price target on the company's stock. The company is conducting a pilot program to gain insights into the home sleep testing process and potential patient benefits.
These developments reflect recent advancements and strategic initiatives by iRhythm Technologies as it continues to innovate and expand its offerings in the digital healthcare sector.
InvestingPro Insights
Wolfe Research's upgrade of iRhythm Technologies (NASDAQ:IRTC) to Outperform with a price target of $115 is indeed a positive signal for potential investors. To provide further context to this outlook, InvestingPro data reveals compelling metrics for the company. With a market capitalization of $3.05 billion, iRhythm Technologies is trading at a high Price / Book multiple of 33.82 as of Q1 2024. Despite not being profitable in the last twelve months, the company has a strong gross profit margin of 66.96%, indicating efficient cost management relative to its revenues of $513.17 million over the same period.
Two InvestingPro Tips to consider are the analysts' revisions of earnings downwards for the upcoming period and the anticipation that the company will not be profitable this year. These insights suggest caution for investors looking for immediate profitability, but the company's solid revenue growth of 19.35% in the last twelve months and its liquid assets exceeding short-term obligations point to a robust financial position that may support long-term growth.
For those interested in a deeper dive into iRhythm Technologies' financial health and future prospects, InvestingPro offers additional tips. Currently, there are 6 more InvestingPro Tips available for IRTC, which can be accessed with a subscription that comes with an extra 10% off for annual or biannual Pro and Pro+ plans using the promo code PRONEWS24.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.